BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients

26 Mar 2025 07:00 CET

The article identifies promising survival results in relapsed/refractory AML
patients

warranting further study

Bergen, Norway - 26 March 2025- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, today announces the publication of a peer-reviewed article
entitled "Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine
in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy" in the
journalNature Communications.

This article is accessible here: www.nature.com/articles/s41467-025-58179-6.pdf

The article highlights results in 36 patients treated with a combination of
BerGenBio's selective oral AXL inhibitor bemcentinib in combination with low
-dose cytarabine(LDAC) chemotherapy. Overall, patients who received the
combination had an overall survival of 7.8 months, substantially longer than
that expected in this difficult-to-treat patient population.

The lead investigator of the study, Professor Sonja Loges, MD, PhD. of the
German Cancer Research Center (DKFZ), Heidelberg, Germany stated, "Following
first line treatment of AML, most patients will relapse, and beyond first line
the prognosis of older patients with relapsed or refractory AML, the population
studied in BGBC003 is particularly poor. With other treatment approaches, the
current overall survival of R/R AML patients is believed to be approximately 2.9
-4 months.  The authors of this article believe that the BGBC003 results in this
population warrant further study."

Olav Hellebo, CEO of BerGenBio commented "Our BGBC003 study evaluated
bemcentinib in relapsed/refractory (R/R) AML patients who have limited effective
treatment options today.  The presence of AXL is a poor prognostic factor in
this population and AXL is believed to promote chemotherapy resistance and
decreased antitumor immune response.  We believe, as a highly selective AXL
inhibitor, bemcentinib holds promise as a treatment for these patients with
extremely high unmet medical needs."

Contacts

Olav Hellebo, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with
a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit?www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site